Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
株式のランク #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
株価
$0.16328419
時価総額
$204.14K
変化(1日)
4.35%
変化(1年)
102.45%
GB
取引 Fusion Antibodies plc (FAB)

カテゴリー

Fusion Antibodies plc(FAB)の営業利益率
March 2026 時点の営業利益率 TTM: -118.73%
Fusion Antibodies plc の最新の財務報告と株価によると、現在の営業利益率(TTM)は -118.73% です。2024 年末時点では -201.41% でした。
Fusion Antibodies plc の営業利益率の履歴(2013 から 2026)
各年末の営業利益率
営業利益率 変化
2026 (TTM) -118.73% 31.15%
2025 -90.53% -55.05%
2024 -201.41% 106.24%
2023 -97.66% 251.80%
2022 -27.76% -16.16%
2021 -33.11% 15.77%
2020 -28.60% -58.63%
2019 -69.14% -3,080.17%
2018 2.32% -64.90%
2017 6.61% 253.48%
2016 1.87% -117.22%
2015 -10.86% -34.26%
2014 -16.52% -85.86%
2013 -116.84% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差
41.30% -100.35%
DK
35.45% -100.30%
US
24.95% -100.21%
US
25.32% -100.21%
BE
25.64% -100.22%
NL
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。